Bispecific antibody · Immune activation, directed at CD3 (CD3E) and somatostatin receptor 2 (SSTR2) · developed by Xencor
Tidutamab is a humanized, Fc domain-containing bispecific monoclonal antibody that binds CD3 on T cells and somatostatin receptor 2 (SSTR2) on cancer cells. Cross-linking the two may trigger a cytotoxic T-lymphocyte response against SSTR2-expressing cells. It is being studied in Merkel cell carcinoma and small cell lung cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04590781 | Phase 1/2 | Merkel Cell Carcinoma | Terminated | XNCR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Merkel Cell CarcinomaSmall Cell Lung Cancer
Updated Nov 1, 2026. Something wrong or missing? Report it on the XNCR page.
See XNCR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
XNCR catalysts and pipeline →